Apoyo y fuentes

Señalamos organizaciones y fuentes publicadas en las que confiamos. igg4.org es independiente, sin financiación ni patrocinio de la industria. Una mención aquí es un reconocimiento, no un filtro.

Literatura médica principal

Las fuentes publicadas en las que se basa este sitio. Cuando es posible, enlazamos a una versión que puede leer completa; si no, al registro de la publicación. Es información y no sustituye a su especialista.

1.Della-Torre E, Talarico R, Ballarin J, et al. Identification of red flags for IgG4-related disease: an international European Reference Network for Rare Connective Tissue Diseases framework. Lancet Rheumatol 2025;7(1):e64-e71
Ver fuente
2.Wallace ZS, Naden RP, Chari S, et al. The 2019 ACR/EULAR classification criteria for IgG4-related disease. Arthritis Rheumatol 2020;72(1):7-19
Ver fuente
3.Wallace ZS, Katz G, Hernandez-Barco YG, Baker MC. Current and future advances in practice: IgG4-related disease. Rheumatol Adv Pract 2024;8(2):rkae020
Ver fuente
4.Iaccarino L, Talarico R, Scire CA, et al. IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open 2019;4(Suppl 1):e000787
Ver fuente
5.Sina S, Bonisoli GL, et al. Clinicopathological pearls and diagnostic pitfalls in IgG4-related disease. Diagnostics 2025;15(18):2299
Ver fuente
6.Maritati F, Peyronel F, Vaglio A. IgG4-related disease: a clinical perspective. Rheumatology 2020;59(Suppl 3):iii123-iii131
Ver fuente
7.Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 2015;67(7):1688-1699
Ver fuente
8.Stone JH, et al. Inebilizumab for treatment of IgG4-related disease. New England Journal of Medicine, 2025.
Ver fuente
9.Cagnotto G, Backlund RT, Bengtsson A, Bruschettini M. Immunosuppressants for IgG4-related disease (protocol). Cochrane Database Syst Rev 2025;(8):CD016094
Ver fuente
10.Cuéllar MC, et al. Enfermedad relacionada a IgG4. Serie clínica de pacientes chilenos. Rev Med Chile 2022;150:705-710.
Ver fuente
11.Lanzillotta M, Campochiaro C, Mancuso G, et al. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. Rheumatology (Oxford) 2020;59:2435-2442.
Ver fuente
12.Okazaki K (ed.). IgG4-Related Disease. Current Topics in Microbiology and Immunology, vol. 401. Springer International Publishing, 2017.
Ver fuente
13.Orozco Gálvez O. Enfermedad relacionada con la IgG4: creación de un algoritmo diagnóstico y terapéutico europeo y nuevas técnicas de medicina nuclear. Doctoral thesis, Universitat Autònoma de Barcelona, 2024.
Ver fuente
14.Bateman AC, Culver EL. Challenges and pitfalls in the diagnosis of IgG4-related disease. Semin Diagn Pathol 2024;41(2):45-53
Ver fuente
15.Reisch M, Spindelböck WJ, Hodl I, Pietsch D, Rainer F, Kickinger D, Sutic A, Thiel J, Stradner M. Azathioprine as maintenance therapy for IgG4-related diseases. Rheumatology International 2026;46(3):47.
Ver fuente
16.Hammitzsch A, Ferraro N, Bachmann Q, Heemann U, Moog P. Long-term treatment patterns and outcomes in IgG4-related disease: a retrospective single-center cohort study focusing on rituximab. Rheumatology International 2026;46:33.
Ver fuente
17.Taranto S, Bernardo L, Mauro A, Perrone A, Tamborino A, Giani T. IgG4-Related Disease in Childhood: Clinical Presentation, Management, and Diagnostic Challenges. Children (Basel) 2025;12(7):888.
Ver fuente
18.González-García A, Starita-Fajardo G, Lucena López D, Iranzo Alcolea MP, et al. New Developments in the Treatment of IgG4-Related Disease: A Comprehensive Clinical Approach. J Clin Med 2025;14(19):6774 (literature searched through July 2025).
Ver fuente
19.Peyronel F, Della-Torre E, Maritati F, Urban ML, Bajema I, Schleinitz N, Vaglio A. IgG4-related disease and other fibro-inflammatory conditions. Nat Rev Rheumatol 2025;21(5):275-290.
Ver fuente
20.Stone JH. IgG4-related disease: lessons from the first 20 years. Rheumatology (Oxford) 2025;64(Suppl 1):i24-i27.
Ver fuente
21.Arias-Intriago M, Gomolin T, Jaramillo F, et al. IgG4-Related Disease: Current and Future Insights into Pathological Diagnosis. Int J Mol Sci 2025;26(11):5325.
Ver fuente
22.Khurram SA, Gueiros LAM, Soares CD, Fonseca FP. IgG4-Related Disease. In: Lymphoproliferative and Granulomatous Disorders of the Oral Cavity. Springer, 2025:207-213.
Ver fuente
23.Hao Q, Lian D, Zhou M, et al. Identification of candidate biomarkers for diagnosis, disease activity, and relapse prediction in IgG4-related disease. Arthritis Res Ther 2026;28(1):96
Ver fuente
24.Della-Torre E, Baker MC, Zhang W, et al; INDIGO Trial Investigators. Obexelimab for the Treatment of IgG4-Related Disease. N Engl J Med, published online 2 June 2026.
Ver fuente
25.Stone JH, Carruthers M, Baker MC, et al. A phase 2 trial of rilzabrutinib in IgG4-related disease. Annals of the Rheumatic Diseases, 2026.
Ver fuente
26.Duru N, van der Goes MC, Jacobs JWG, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72(12):1905-1913.
Ver fuente
27.Beuschlein F, Else T, Bancos I, et al. European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency. J Clin Endocrinol Metab 2024;109(7):1657-1683
Ver fuente
28.Fong AC, Cheung NW. The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res Clin Pract 2013;99(3):277-280
Ver fuente
29.Nuthalapati M, Menon AR, Rajendran R, et al. IgG4-Related Disease in Urological Practice: A Case Series of Mistaken Malignancies. Indian J Surg Oncol 2025;16(6):1446-1451.
Ver fuente
30.Tomkins M, Martin-Grace J, Kennedy C, et al. Adrenal insufficiency is common amongst kidney transplant recipients receiving maintenance prednisolone and can be predicted using morning cortisol. Nephrol Dial Transplant 2023;38(1):236-245
Ver fuente
31.Mahajan A, Tinianow A, Katz G. IgG4-Related disease: From diagnosis to remission. Best Practice & Research Clinical Rheumatology 2025;39:102108.
Ver fuente
32.Peng L, Nie Y, Zhou J, et al. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial. Ann Rheum Dis 2024;83(5):651-660
Ver fuente
33.2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, European Alliance of Associations for Rheumatology
Ver fuente
34.Choosing Wisely Canada, Allergy and Clinical Immunology recommendations, Canadian Society of Allergy and Clinical Immunology, updated May 2025
Ver fuente
35.Yang F, Wang T, Liu Y. Risk factors for relapse of IgG4-related disease: a systematic review and meta-analysis. Clin Rheumatol 2025;44:4137-4147
Ver fuente
36.Angarola E, Pasqua A, Castro HM, Cáceres A, Spina JC, Casciato P. Clinical characteristics, disease course, and chronic organ damage in a real-world cohort of IgG4-related disease: insights from an Interdisciplinary Unit. Medicina Clínica 2026;166:107317
Ver fuente
37.Peyronel F, Palmisano A, Maritati F, et al. Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial. J Autoimmun 2025;157:103487
Ver fuente
38.Koster MJ, Ghaffar U, Duong SQ, et al. Incidence, prevalence and mortality of chronic periaortitis: a population-based study. Clin Exp Rheumatol 2022;40:751-757
Ver fuente
39.Dattani R, Barwick TD, El Wardany G, et al; RaDaR Rare Disease Group. An international patient-centred study of retroperitoneal fibrosis. QJM 2022;115(3):148-154
Ver fuente
40.Tang H, Yang H, Zhang P, et al. Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China. Sci Rep 2020;10:4910
Ver fuente
41.So H, Choi SJ, Park S, et al. Increased cancer risk in patients with IgG4-related disease in a nationwide South Korean cohort, 2012-2021. Sci Rep 2025;15:37273
Ver fuente
42.American College of Rheumatology. IgG4-Related Disease (IgG4-RD). Patient information page, updated February 2025.
Ver fuente
43.Gwozdz-Broczkowska A. Fatigue beyond inflammation in inflammatory rheumatic diseases: a narrative review and treatable-traits framework. Rheumatol Int 2026;46(8):232.
Ver fuente
44.US Food and Drug Administration. RAYOS (prednisone) delayed-release tablets, prescribing information, revision 12/2019.
Ver fuente
45.Liu Q, Zheng Y, Sturmlechner I, et al. IKZF1 and UBR4 gene variants drive autoimmunity and Th2 polarization in IgG4-related disease. J Clin Invest 2024;134(16):e178692.
Ver fuente
46.FAI2R. Maladie associee aux IgG4: les reponses a vos questions.
Ver fuente
47.Russell MD, Dey M, Flint J, et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2023;62(4):e48-e88.
Ver fuente
48.European Medicines Agency. MabThera (rituximab), Summary of Product Characteristics.
Ver fuente
49.European Medicines Agency. Nordimet (methotrexate), Summary of Product Characteristics.
Ver fuente
50.US Food and Drug Administration. IMURAN (azathioprine) 50-mg scored tablets, product information, revision 12/2018.
Ver fuente
51.Yu K, Gao H, Liu S, et al. Perception of recurrence risk in patients with IgG4-related disease: a descriptive phenomenological study. Rheumatol Adv Pract 2025;9(1):rkae148.
Ver fuente
52.Newman JH, Shaver A, Sheehan JH, et al; Undiagnosed Disease Network. IgG4-related disease: Association with a rare gene variant expressed in cytotoxic T cells. Mol Genet Genomic Med 2019;7(6):e686.
Ver fuente
53.Karamya ZA, Kovacs A, Illes D, Czako B, Fazekas A, Farkas N, Hegyi P, Czako L. Prevalence of autoimmune pancreatitis in pancreatic resection for suspected malignancy: a systematic review and meta-analysis. BMC Gastroenterol 2024;24:278.
Ver fuente
54.Dures E, Farisogullari B, Santos EJF, et al. 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 2024;83(10):1260-1267.
Ver fuente
55.Motor J, Gajewska A, Cienkowski K, et al. IgG4-related disease: focus on digestive system involvement. Front Immunol 2025;16:1584107.
Ver fuente
56.Orphanet. Enfermedad sistemica relacionada con IgG4 (ORPHA:596448), Spanish version.
Ver fuente
57.Orphanet. IgG4-gerelateerde systemische ziekte (ORPHA:596448), Dutch version.
Ver fuente
58.Orphanet. Maladie systemique liee a la presence d'anticorps IgG4 (ORPHA:596448), French version.
Ver fuente
59.Orphanet. IgG4-related systemic disease (ORPHA:596448), German version.
Ver fuente
60.European Medicines Agency. Uplizna (inebilizumab), European public assessment report.
Ver fuente
61.Erasmus MC. IgG4-gerelateerde ziekte, patient information.
Ver fuente
62.Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015;74(6):1171-1177.
Ver fuente
63.Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLoS One 2017;12(9):e0183844.
Ver fuente
64.ClinicalTrials.gov registry record NCT04520451. An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008/SAR444671) on Safety and Disease Activity in Participants With IgG4-Related Disease. Phase 2, completed. Sponsor: Principia Biopharma, a Sanofi Company.
Ver fuente
65.ClinicalTrials.gov registry record NCT07190196. A Randomized, Phase 3, Double-blind, 52-week Study to Evaluate the Efficacy and Safety of Rilzabrutinib (SAR444671) Compared to Placebo in Adult Participants With Active IgG4-related Disease (RILIEF). Recruiting. Sponsor: Sanofi.
Ver fuente
66.Stapel SO, Asero R, Ballmer-Weber BK, Knol EF, Strobel S, Vieths S, Kleine-Tebbe J; EAACI Task Force. Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report. Allergy 2008;63(7):793-796.
Ver fuente
67.Orphanet. IgG4-related systemic disease (ORPHA:596448).
Ver fuente
68.Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS). Ficha tecnica prednisona, CIMA.
Ver fuente
69.Protocole National de Diagnostic et de Soins (PNDS), Maladie associee aux IgG4. Haute Autorite de Sante, with FAI2R and CERAINOM-IgG4, November 2025.
Ver fuente
70.Het Oogziekenhuis Rotterdam. IgG4-gerelateerde orbitale ziekte, patient information.
Ver fuente
71.Imperial College Healthcare NHS Trust. RPF and IgG4-RD (retroperitoneal fibrosis and immunoglobulin-4 related disease), specialist nephrology service.
Ver fuente

National clinical guidance

Los enlaces siguientes llevan fuera de este sitio, para ayudarle a seguir buscando por su cuenta. No los controlamos ni los respaldamos, y no obtenemos nada por incluirlos. A diferencia de nuestras propias fuentes anteriores, no los verificamos en cuanto a origen o exactitud. Confirme siempre lo importante con su especialista.

1.Protocole National de Diagnostic et de Soins (PNDS), Maladie associee aux IgG4, Haute Autorite de Sante, FAI2R and CERAINOM-IgG4, November 2025.
Ver fuente

Product information (regulatory)

1.Ficha técnica prednisona, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA
Ver fuente

Patient information from specialist centres

1.Het Oogziekenhuis Rotterdam, IgG4-Gerelateerde Orbitale Ziekte (IgG4-related orbital disease), patient information. Recognised Dutch expertise centre for rare orbital conditions.
Ver fuente
2.Imperial College Healthcare NHS Trust, RPF and IgG4-RD service: specialist multidisciplinary service for retroperitoneal fibrosis and IgG4-related disease.
Ver fuente

Sitios web útiles

Este asistente comparte información con fuentes y no puede diagnosticarte ni sustituir a tu médico. En una urgencia, busca atención urgente primero.

De los mismos autores: Balanced Divinity